Indoco receives USFDA nod for Goa facility; rallies 14%
,
India Infoline News Service | Mumbai | May 25, 2016 15:38 IST
This approval confirms the closure of inspection conducted in July'2015.
Indoco Remedies Ltd has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its sterile and solid dosages facility (Goa Plant II) situated at L-32/33/34 Verna Industrial Estate, Goa. This approval confirms the closure of inspection conducted in July'2015.
The stock closed l4% higher at Rs.299.
The scrip opened at Rs. 265.85 and has touched a high and low of Rs. 309 and Rs. 265.85 respectively. So far 716885(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 2424.93 crore.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 413.1 on 25-May-2015 and a 52 week low of Rs. 244 on 25-Feb-2016. Last one week high and low of the scrip stood at Rs. 272 and Rs. 258.25 respectively.
The promoters holding in the company stood at 59.25 % while Institutions and Non-Institutions held 20.78 % and 19.98 % respectively.
The stock is currently trading above its 200 DMA.
|
|